An AI Found a Zoom Bug in One Day That Would Normally Take a Team Six Months August 14, 2026August 14, 2026
Cullinan’s Cancer Drug Worked So Well the Trial’s Watchdog Said Stop Pretending August 14, 2026August 14, 2026
Two targets, one molecule: a bispecific from chinese Akeso beats a PD-1 inhibitor head to head August 14, 2026August 14, 2026
Regeneron Just Co-Led a $75M Bet on a Startup Coming for Its Own Blockbuster August 14, 2026August 14, 2026
AstraZeneca Sold This Drug for $5 Million. It’s Now Worth Up to $475 Million August 13, 2026August 13, 2026
A Gene That Should Stay Silent Is Poisoning Muscle. A New Drug Just Told It to Shut Up August 13, 2026August 13, 2026
A Heart Drug Europe Has Used for 20 Years Just Failed Its Big American Test August 13, 2026August 13, 2026
Cost of delay, quantified: an AI trial monitor is valued at $21 million per cancer programme August 13, 2026August 13, 2026
Rejected on the factory floor: the FDA turned down a cancer drug without questioning the data August 12, 2026August 12, 2026
Small molecule, big difference: the GLP-1 pill problem was never the receptor August 12, 2026August 12, 2026
Partial inhibition, by design: the rare-disease drug that deliberately stops at 80% August 12, 2026August 12, 2026
Small by design: a camelid-derived Nanobody clears its endpoints in psoriatic arthritis August 10, 2026August 10, 2026
